« Previous
Next »
JAMDA
Volume 10, Issue 1
, Pages
21-27
, January 2009
A Randomized, Double-Blind, Placebo-Controlled Tolerability Study of Intramuscular Aripiprazole in Acutely Agitated Patients With Alzheimer's, Vascular, or Mixed Dementia
-
Mean change in Simpson−Angus Scale Total score from baseline during intramuscular treatment. The Simpson−Angus Scale is a 10-item scale rated from 1 (normal) to 5 (worst), with a negative change on th
Mean change in Simpson−Angus Scale Total score from baseline during intramuscular treatment. The Simpson−Angus Scale is a 10-item scale rated from 1 (normal) to 5 (worst), with a negative change on the Total score (scale 10–50) indicating a reduction in extrapyramidal symptoms.
-
Efficacy outcomes during intramuscular treatment. (A) Mean change in Positive and Negative Syndrome Scale Excited Component (PEC) score from baseline, (B) mean Clinical Global Impression–Improvement (Efficacy outcomes during intramuscular treatment. (A) Mean change in Positive and Negative Syndrome Scale Excited Component (PEC) score from baseline, (B) mean Clinical Global Impression–Improvement (CGI-I) score, (C) mean change in Agitation–Calmness Evaluation Scale (ACES) score from baseline (last observation carried forward data set). The PEC score consists of 5 PANSS items (hostility, lack of cooperation, excitement, poor impulse control, tension), each rated on a scale of 1 (absent) to 7 (extreme). A negative change from baseline in the PEC score (scale 5–35) signifies improvement. The CGI-I score is measured on a scale from 1 (very much improved) to 7 (very much worse), where a lower score signifies greater improvement. The ACES score is assessed on a scale of 1 (marked agitation) to 9 (unarousable); a score of 4 indicates normal; a positive change from baseline signifies improvement.
This study was supported by Bristol-Myers Squibb (Princeton, NJ) and Otsuka Pharmaceutical Co., Ltd. (Tokyo, Japan). Editorial support for the preparation of this manuscript was provided by Ogilvy Healthworld Medical Education; funding was provided by Bristol-Myers Squibb.
PII: S1525-8610(08)00253-3
doi: 10.1016/j.jamda.2008.06.006
© 2009 American Medical Directors Association. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
JAMDA
Volume 10, Issue 1
, Pages
21-27
, January 2009
